Ariplat 10 Injection: Each vial contains Cisplatin BP 10 mg, as sterile preservative free 10 ml concentrated solution for IV Infusion.
Ariplat 50 Injection: Each vial contains Cisplatin BP 50 mg, as sterile preservative free 50 ml concentrated solution for IV Infusion.
Cisplatin binds with DNA to form intrastrand crosslinks and adducts that cause changes in the conformation of the DNA and affect DNA replication. Cisplatin then binds with DNA, RNA, or other macromolecules at two sites to form interstrand and intrastrand links. These intrastrand adducts significantly alter the conformation of DNA and inhibit DNA polymerase, RNA polymerase, RNA translocation, and other key enzymes. Cisplatin causes cell cycle arrest in the G2-phase and then induces programmed cell death or apoptosis. Cisplatin injection is indicated for the treatment of Testicular, Ovarian and Bladder Cancer.
Metastatic Testicular Tumors:
In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
Metastatic Ovarian Tumors:
In established combination therapy (e.g. Cisplatin with Cyclophosphamide) with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy.
Advanced Bladder Cancer:
Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
Administered by slow intravenous infusion. Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to Cisplatin Injection is recommended.
Preparation & Handling:
Plasma levels of anticonvulsant agents may become subtherapeutic during Cisplatin therapy.
Response duration can be adversely affected when pyridoxine is used in combination with hexamethylmelamine and Cisplatin.
Cisplatin is contraindicated in patients with preexisting renal impairment. Cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. Cisplatin is contraindicated in patients with a history of allergic reactions to Cisplatin or other platinum-containing compounds.
Nephrotoxicity:
Dose-related and cumulative renal insufficiency, including acute renal failure.
Ototoxicity:
Tinnitus and/or hearing loss in the high frequency range.
Hematologic:
Myelosuppression, leukopenia, thrombocytopenia, anemia, neutropenia.
Gastrointestinal:
Nausea and vomiting, anorexia, diarrhoea.
Other Toxicities:
Serum electrolyte disturbances, hyperuricemia, neurotoxicity, ocular toxicity, anaphylactic-like reactions, hepatotoxicity.
Pregnancy: Pregnancy category D,
Cisplatin can cause fetal harm. Pregnancy should be avoided during Cisplatin treatment and for at least 14 months after the last dose.
Nursing mothers:
Cisplatin has been reported to be found in human milk; patients receiving Cisplatin should not breast-feed.
Pediatric use:
Safety and effectiveness in pediatric patients have not been established.
Geriatric use:
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.
Renal impaired patients:
Cisplatin is known to be substantially excreted by the kidney and is contraindicated in patients with preexisting renal impairment.
Peripheral blood counts should be monitored weekly. Liver function should be monitored periodically. Neurologic examination should also be performed regularly.
Store in a dry place at temperature below 25 C. Protect from light and do not refrigerate. Keep out of the reach of children.